47/100Is MRNA-Moderna, a buy?
Wednesday 19 August 2026
Why now: A major Phase 3 melanoma readout with Merck is re-framing Moderna as more than a seasonal respiratory-vaccine story, and the market is repricing that optionality immediately. The flip side is that the stock is now in a “prove it” zone where the next steps on regulatory filing and launch planning matter as much as the headline.
Upside: If oncology becomes a credible second pillar and Moderna can stabilize cash burn, the equity can sustain a higher long-term valuation than a respiratory-only narrative. In the near term, the stock’s own move has already front-loaded a lot of upside, so remaining upside depends on follow-through execution rather than just attention.
Risks: Today’s gap-up price action raises the risk of a sharp giveback if the market decides the commercial opportunity and timing are smaller than implied. Separately, the current cash burn profile leaves limited room for execution mistakes without further dilution or deeper cost cuts.
Sign up or log in for access
Unlock the full scorecard, detailed analysis, and research notes. Free — no credit card needed.
Scorecard
| Scorecard | 47/100 | |
|---|---|---|
| Company Detail | MRNA - Moderna, Inc. | |
| Price as at 19 August 2026 | $118.24 | |
| Market cap | $25.0B | |
| Quality and Fundamental Score (100) | ||
| Breakout / Early-Momentum /20 | 14/20 | |
| Rev/EPS Momentum /20 | 0/20 | |
| Business Quality /15 | 7/15 | |
| Balance Sheet /15 | 3/15 | |
| Valuation /10 | 4/10 | |
| Industry Relative Strength /10 | 9/10 | |
| Macro / Sector Tailwind /10 | 10/10 | |
| Growth | ||
| Cash runway | 0.83 yr | |
| Revenue YoY | -39.2% | |
| EPS YoY | +21.7% | |
| FCF YoY | +49.1% | |
| Gross margin | 55.3% | |
| Valuation & Trend | ||
| Trailing P/E | neg | |
| Forward P/E | — | |
| RSI (14d) | 87 | |
| vs 50d SMA | +88.4% | |
| Support cushion | −55.3% | |
| Sentiment | ||
| Wall Street verdict | Disagrees | |
| News tone | Positive | |
| Dividend | — | |
How are these colored?
| Metric | Strong metrics | Solid metrics | Selective | Caution | Unfavourable |
|---|---|---|---|---|---|
| Overall score | ≥ 80 | 70-79 | 60-69 | 50-59 | < 50 |
| Business quality /15 | ≥ 12 | 10-11 | 8-9 | 6-7 | < 6 |
| Balance sheet /15 | ≥ 12 | 10-11 | 8-9 | 6-7 | < 6 |
| Market cap | ≥ $20B | $5B-$20B | $2B-$5B | $1B-$2B | < $1B |
| Cash runway | ≥ 3 yr or cash generative | 1.5-3 yr | 0.75-1.5 yr | 0.25-0.75 yr | < 0.25 yr |
| Revenue YoY | ≥ 15% | 5-15% | 0-5% | -5-0% | < -5% |
| EPS YoY | ≥ 20% | 5-20% | 0-5% | -5-0% | < -5% |
| FCF YoY | ≥ 10% | 1-10% | 0-1% | -5-0% | < -5% |
| Gross margin | ≥ 60% | 40-60% | 25-40% | 10-25% | < 10% |
| Trailing P/E | < 15 | 15-25 | 25-35 | 35-40 | > 40 or neg |
| Forward P/E | < 15 | 15-25 | 25-35 | 35-40 | > 40 or neg |
| RSI (14d) | 50-70 | 45-50 or 70-75 | 40-45 or 75-78 | 30-40 or 78-80 | < 30 or > 80 |
| vs 50d SMA | +2% to +15% | 0-2% or 15-25% | -2-0% or 25-35% | -3--2% or 35-40% | < -3% or > 40% |
| Support cushion | 2-10% above | 0-2% | 10-15% | 15-20% | price below support |
| Wall Street verdict | Aligned | — | Mixed | — | Disagrees |
| News tone | Positive | — | Neutral / Mixed | — | Negative |
| Dividend | Yield ≥ 2% & growing | Growing | Flat payer ≥ 1% | Low / flat | Cutting |
Detailed Analysis — Wednesday 19 August 2026
Stéphane Bancel has been Chief Executive Officer and a Director of Moderna since 2011.
James Mock is Moderna’s Chief Financial Officer.
Receiver of capital expenditure: No — Moderna sells regulated medicines and vaccines; its demand is driven by public health recommendations, payor coverage, and procurement decisions rather than customers funding large capital equipment builds.
Main customers
- Government and public health purchasers (US and international) (Buy vaccines for eligible populations through public procurement and immunization programs.)
- Pharmacies and retail clinics (Administer seasonal vaccines and drive patient access during respiratory virus season.)
- Hospitals and health systems (Administer vaccines and oncology treatments through clinical pathways and formularies.)
Notable contracts
- Merck collaboration for individualized neoantigen therapy intismeran autogene (mRNA-4157/V940) with KEYTRUDA (Co-development partnership focused on adjuvant and other settings across multiple tumor types; today’s catalyst is Phase 3 INTerpath-001 in resected melanoma meeting key endpoints.)
- Moderna has a real platform with repeated regulatory and clinical execution in vaccines, and today’s oncology Phase 3 headline materially improves the “second act” narrative.
- However, the current financial profile is still weak, so the investment case hinges on converting a broadened pipeline into durable revenue while reducing cash burn.
- From here, the business can get better, but the stock price is now demanding faster proof.
Show 1 headline from the last 7d
Scores 47 out of 100 — a mixed overall grade. Sector fit and relative strength versus its industry scored highest. Chart setup was fair but not a standout driver. Business quality and valuation weighed on the total. The score is capped by current fundamentals (large net losses and negative free cash flow with a short cash runway) and by today’s extreme gap-up, which creates real drawdown risk even if the long-term story improves. Mechanical cap: latest annual net income ≤ 0 — Balance Sheet ≤ 3/15, Rev/EPS ≤ 0/20, overall ≤ 50/100.
Component scores are on the scorecard above.
- The stock is in an extreme momentum state: last trade is far above the prior close and the prior daily-bar snapshot already showed a very extended condition.
- This is a strength signal for relative performance in biotech, but it also means near-term risk is dominated by volatility and potential gap-fill behavior rather than a clean, low-risk technical setup.
- Moderna’s latest annual revenue is $1.94B with a net loss of $2.82B and negative free cash flow of $2.06B, which is not consistent with a self-funding growth story today.
- The balance sheet shows $1.72B of cash and a computed cash runway of about 0.83 years, so execution and cost control are urgent, not optional.
- Profitability metrics are deeply negative (ROE, ROIC, and ROA all negative), and the Piotroski score of 2 is a red flag for current financial momentum despite a still-healthy current ratio of about 2.29 and an Altman Z-score of about 3.86.
Cash runway: 0.83 yr ($1.7B cash ÷ $2.1B/yr burn, latest fiscal year).
Upcoming (1–6 months)
- Regulatory and commercialization next steps for intismeran autogene plus KEYTRUDA following the Phase 3 INTerpath-001 headline.
- Early respiratory-season demand signals for Moderna’s approved products, including RSV vaccine uptake.
Ongoing
- Quarterly cash burn and the company’s ability to extend cash runway without heavy dilution.
Risks
- The melanoma opportunity may be smaller, slower to monetize, or more competitive than the stock’s reaction implies, which could compress valuation even if the science is sound.
- Negative free cash flow and a short cash runway increase the chance of dilution or forced spending cuts that slow the pipeline.
Breaks the thesis
- A sustained breakdown that loses the prior breakout reference near $85.58 on a closing basis, paired with worsening cash runway or guidance, would signal the re-rate is failing to convert into a durable trend.